Glioma-Associated Gangliosides

  • P. Fredman
Conference paper
Part of the NATO ASI Series book series (volume 7)

Abstract

Gliomas, which account for almost half of all central nervous system tumors (1), often affect middle-aged individuals and cause severe social problems. In the US approx. 20,000 cases per year are reported. The corresponding figure for Sweden is 300, and in the Federal Republic of Germany the incidence is estimated to 1/10,000. The prognosis for the malignant forms is very bad, and despite surgical excision followed by irradiation and chemotherapy there has not been any significant increase of the surrival time, which is approx. one year. This might be attributed to a number of factors such as the invasive growth, without sharp delimitation from surrounding normal tissue, the great heterogeneity within the same tumor and the lack of knowledge about the biology of the tumors. Monoclonal antibodies to tumor-associated antigens could prove very helpful in increasing our knowledge of the biology of gliomas and in improving diagnosis and therapy. However, the usefulness of such an antibody depends on its specificity, and those produced so far have shown questionable specificity (2).

Keywords

Hydrolysis Migration Carbohydrate Adenocarcinoma Glycol 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Russel DC, Rubinstein LJ (eds) (1977) Pathology of tumours of the nervous system. William and Wilkins Co, Baltimore.Google Scholar
  2. 2.
    Bourdon MA, Coleman RE, Bigner DD (1984) The potential of monoclonal antibodies as carrier of radiation and drugs for immunodetection and therapy of brain tumours, in Prog Exp Tumor Res (eds ML Rosenblum and CB Wilson) Karger AC, Basel 28: 79–101.Google Scholar
  3. 3.
    Ando S (1983) Gangliosides in the nervous system. Neurochem Int 5: 507–537.PubMedCrossRefGoogle Scholar
  4. 4.
    Hakomori S (1984) Tumor-associated carbohydrate antigen. Ann Rev Immunol 2: 103–126.CrossRefGoogle Scholar
  5. 5.
    Hakomori S (1985) Aberrant glycosylation in cancer cell membrane as focused on glycolipids: overview and prespectives. Cancer Res 45: 2405–2414.PubMedGoogle Scholar
  6. 6.
    Feizi T (1985) Demonstration by monoclonal antibodies that carbohydrate structures of glycoproteins and glycolipids are onco-developmental antigens. Nature 314: 53–57.PubMedCrossRefGoogle Scholar
  7. 7.
    Zülch KJ (1979) Histological typing of tumours of the central nervous system. International histological classification of tumours No 21. World Health organization, Geneva.Google Scholar
  8. 8.
    Fredman P, von Hoist H, Collins VP, Ammar A, Dellheden B, Wahren B, Granholm L, Svennerholm L (1985) Potential ganglioside antigens associated with human gliomas. Neurol Res 8: 123–126.Google Scholar
  9. 9.
    Seifert H (1966) Über ein weiters hirntumor characteristiches gangliosid. Klin Wochenschr 44: 469–470.PubMedCrossRefGoogle Scholar
  10. 10.
    Kostic’ D, Buchheit F (1970) Gangliosides in human brain tumours. Life Sciences 9: 589–596.CrossRefGoogle Scholar
  11. 11.
    Yates AJ, Thompson DK, Baesel CP, Albrightson C, Hart RW (1979) Lipid composition of human neural tumours. J Lipid Res 20: 428–43.PubMedGoogle Scholar
  12. 12.
    Traylor DT, Hogan EL (1980) Gangliosides of cerebral astrocytomas. J Neurochem 34: 126–131.PubMedCrossRefGoogle Scholar
  13. 13.
    Eto S, Shinoda S (1982) Gangliosides and neutral glycosphingolipids in human brain tumors: specificity and their significance. Adv Exp Med Biol 152: 279–290.PubMedGoogle Scholar
  14. 14.
    Berra B, Gaini SM, Riboni L (1985) Correlation between ganglioside distribution and histological grading of human astrocytoma. 36: 363–366.Google Scholar
  15. 15.
    Berra B, Riboni L, de Gasperi R, Gaini SM, Ragnotti G (1983) Modification of ganglioside patterns in human meningiomas. J Neurochem 40: 777–782.PubMedCrossRefGoogle Scholar
  16. 16.
    Baumann N, Harpin, ML, Turpin JC (1981) Ganglioside content and pattern in tumor tissue of human neuroblastomas. Biomedicine 35: 215–217.PubMedGoogle Scholar
  17. 17.
    Schengrund C-L, Repman MA, Shochat SJ (1985) Ganglioside composition of human neuroblastomas 56: 2640–2646.Google Scholar
  18. 18.
    Wu Z-L, Schwartz E, Seeger R, Ladisch S (1986) Expression of GD2 ganglioside by untreated primary human neuroblastomas. Cancer Res 46: 440–443.PubMedGoogle Scholar
  19. 19.
    Peak JD, Berry PJ, Pennock CA (1986) Abnormal ganglioside in neuroblastoma. Lancet June 14.Google Scholar
  20. 20.
    Schuby G, Cheresh DA, Varki NM, Yu A, Staffileno LK, Reisfeld RA (1984) Detection of ganglioside GD2 in tumor tissues and sera of neuroblastoma patients. Cancer Res 44: 5914–5920.Google Scholar
  21. 21.
    Ladisch S, Wu Z-L (1985) Detection of a tumour-associated ganglioside in plasma of patients with neuroblastomas. Lancet i 136–138.Google Scholar
  22. 22.
    Portoukalian J, Zwingelstein G, Doré J-F (1979) Lipid compositon of human malignant melanoma tumors at various levels of malignant growth. Eur J Biochem 94: 19–23.PubMedCrossRefGoogle Scholar
  23. 23.
    Månsson J-E, Fredman P, Nilsson O, Lindholm L, Holmgren J, Svennerholm L (1985) Chemical structure of carcinoma ganglioside antigens defined by monoclonal antibody C-50 and some allied gangliosides of human pancreatic adenocarcinoma. Biochim Biophys Acta 834: 110–117.PubMedGoogle Scholar
  24. 24.
    Hoshino T, Namura K, Wilson CB, Knebel KD, Gray JW (1978) The distribution of nuclear DNA from human brain tumor cells. J Neurosurg 49: 13–21.PubMedCrossRefGoogle Scholar
  25. 25.
    Bigner DD, Bigner SH, Pontén J, Westermark B, Mahaley MS, Ruoslahti E, Herschmann E, Eng LF, Wikstrand CJ (1981) Heterogeneity of genotypic and phenotypic characteristics of fifteen permanent cell lines derived from human gliomas. J Neuropath Exp Neurol 40: 201–229.PubMedCrossRefGoogle Scholar
  26. 26.
    Fredman P, Svennerholm L, Wikstrand CJ, Bigner SH, Mark J, Bigner DD (1986) Canglioside in eleven different established human glioma cell lines. Submitted to J Neuropath Exp Neurol.Google Scholar
  27. 27.
    Holmgen J, Lindblad M, Fredman P, Svennerholm L, Myrvold H (1985) Comparison of receptors for Cholera and Esherichia coli enterotoxins in human intestine. Gastroenterology 89: 27–35.Google Scholar
  28. 28.
    Manuelidis L, Yu RK, Manuelidis EE (1977) Canglioside content and pattern in human gliomas in culture. Acta Neuropath 38: 129–135.PubMedCrossRefGoogle Scholar
  29. 29.
    Poduslo SE, Miller K, Jang Y (1983) Comparison of lipid metabolism in a human glioma cell line, its clone and Oligodendroglia. Cancer Res 43: 1014–1018.PubMedGoogle Scholar
  30. 30.
    Coulon-Morelec M-J, Buc-Caron M-H (1981) Lipid patterns of embryonal carcinoma cell lines and their derivatives: Changes with differentiation. Dev Biology 83: 278–290.CrossRefGoogle Scholar
  31. 31.
    Liepkalns VA, Icard C, Yates AJ, Thompson DK, Hart, RW (1981) Effects of cell density on lipids of human glioma and fetal neural cells. J Neurochem 36: 1959–1965.PubMedCrossRefGoogle Scholar
  32. 32.
    Liepkalns VA, Icard-Liepkalns C, Yates AJ, Mattison S, Siephens RE (1983) Effects of human brain cell culture conditions on C-glucos-amine radioactivity incorporation into gangliosides. J Lipid Res 24: 533–540.PubMedGoogle Scholar
  33. 33.
    Månsson J-E, Fredman P, Bigner DD, Molin K, Rosengren B, Friedman HS, Svennerholm L (1986) Characterization of new gangliosides of the lactotetraose series in murine xenografts at a human glioma cell line. Febs Lett 201: 109–113.PubMedCrossRefGoogle Scholar
  34. 34.
    Fukuda MN, Bothner B, Lloyd K, Rettig WJ, Tiller PR, Dell A (1986) Structures of glycosphinglipids isolated from human embryonal carcinoma cells. J Biol Chem 261: 5145–5153.PubMedGoogle Scholar
  35. 35.
    Nilsson O, Månsson J-E, Lindholm L, Holmgren J, Svennerholm L (1985) Sialyllactotetraosylceramide a novel ganglioside antigen detected in human carcinomas by a monoclonal antibody. Febs Lett 182: 398–402.PubMedCrossRefGoogle Scholar
  36. 36.
    Molin K, Månsson J-E, Fredman P, Svennerholm L (1986) Sialosyllactotetraosylceramide 3′-LM1, a ganglioside of the lactotetraose series isolated from normal human infant brain. Submitted to J Neurochem.Google Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1987

Authors and Affiliations

  • P. Fredman
    • 1
  1. 1.Department of Psychiatry and NeurochemistryGothenburg University St. Jörgen HospitalHisings BackaSweden

Personalised recommendations